Seer (NASDAQ:SEER – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01, FiscalAI reports. Seer had a negative net margin of 506.15% and a negative return on equity of 25.10%. The company had revenue of $4.12 million during the quarter, compared to analysts’ expectations of $4.00 million. Seer updated its FY 2025 guidance to EPS.
Seer Stock Down 4.2%
NASDAQ:SEER traded down $0.09 on Friday, hitting $2.07. The stock had a trading volume of 242,829 shares, compared to its average volume of 198,637. The company has a fifty day moving average price of $2.17 and a two-hundred day moving average price of $2.11. Seer has a 1-year low of $1.62 and a 1-year high of $2.63. The stock has a market cap of $116.62 million, a price-to-earnings ratio of -1.49 and a beta of 1.59.
Insider Activity at Seer
In related news, CEO Omid Farokhzad sold 33,992 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $2.04, for a total value of $69,343.68. Following the transaction, the chief executive officer directly owned 1,272,068 shares in the company, valued at approximately $2,595,018.72. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 11.28% of the company’s stock.
Institutional Investors Weigh In On Seer
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.
Check Out Our Latest Stock Report on Seer
Seer Company Profile
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
See Also
- Five stocks we like better than Seer
- The Most Important Warren Buffett Stock for Investors: His Own
- Dave Stock: 180% Gain + Q3 Beat = Breakout Setup?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Cameco Stock Falls After Earnings, Why the Dip May Be a Gift
- How to Calculate Return on Investment (ROI)
- Amgen Stock: New All-Time Highs Ahead After Earnings Beat
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.
